TransCode Therapeutics Inc (NASDAQ:RNAZ) has a beta value of 0.61 and has seen 2.57 million shares traded in the last trading session. The company, currently valued at $12.09M, closed the last trade at $0.70 per share which meant it lost -$0.03 on the day or -4.03% during that session. The RNAZ stock price is -2928.57% off its 52-week high price of $21.20 and 68.57% above the 52-week low of $0.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.39 million shares traded. The 3-month trading volume is 2.08 million shares.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Sporting -4.03% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RNAZ stock price touched $0.70 or saw a rise of 12.5%. Year-to-date, TransCode Therapeutics Inc shares have moved -89.38%, while the 5-day performance has seen it change 18.78%. Over the past 30 days, the shares of TransCode Therapeutics Inc (NASDAQ:RNAZ) have changed 176.68%. Short interest in the company has seen 1.38 million shares shorted with days to cover at 0.45.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Figures show that TransCode Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 12.67% over the past 6 months, with this year growth rate of 98.01%, compared to 19.10% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -28.81% over the past 5 years.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Insiders own 0.03% of the company shares, while shares held by institutions stand at 11.46% with a share float percentage of 11.47%. Investors are also buoyed by the number of investors in a company, with TransCode Therapeutics Inc having a total of 17.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund . As of Aug 31, 2024 , the former fund manager holds about 0.21% shares in the company for having 36.71 shares of worth $25696.0 while later fund manager owns 1.09 shares of worth $766.0 as of Aug 31, 2024 , which makes it owner of about 0.01% of company’s outstanding stock.
